Veronika Felber, Nadine Holzleitner, Thomas Günther
{"title":"Synthesis and in vitro evaluation of pharmacokinetically optimized 99mTc-labeled cholecystokinin-2 receptor-targeted peptides for improved SPECT imaging","authors":"Veronika Felber, Nadine Holzleitner, Thomas Günther","doi":"10.1186/s41181-026-00477-5","DOIUrl":"10.1186/s41181-026-00477-5","url":null,"abstract":"<div><h3>Background</h3><p>Hitherto, clinically applied <sup>99m</sup>Tc-based cholecystokinin-2 receptor (CCK-2R) ligands suffer from limited in vivo stability. Therefore, we focused on the development of pharmacokinetically optimized <sup>99m</sup>Tc-labeled CCK-2R ligands for improved imaging of CCK-2R-overexpressing malignancies via single-photon emission computed tomography (SPECT). The novel CCK-2R ligands were designed based on the recently published compounds CCK-66, rhCCK-18 and rhCCK-84.</p><h3>Results</h3><p>CCK-2R ligands were prepared by solid-phase peptide synthesis (SPPS) and <sup>99m</sup>Tc-labeled via the tetraamine (N<sub>4</sub>) chelator (95 °C, 15 min) with final radiochemical purities ≥ 95% (radiochemical yields > 99%, n = 39), as determined by radio-RP-HPLC. Affinity (IC<sub>50,inverse</sub>) and internalization experiments were performed using CCK-2R<sup>+</sup> AR42J cells. Lipophilicity (logD<sub>7.4</sub>), human serum albumin (HSA) binding and stability in human serum (4 h, 37 °C) was determined as well. Four of the seven novel CCK-2R ligands, i.e. [<sup>99m</sup>Tc]Tc-N<sub>4</sub>-CCK-66 and [<sup>99m</sup>Tc]Tc-N<sub>4</sub>-CCK-103 to -105, exhibited similar CCK-2R affinities compared to the reference ligands [<sup>177</sup>Lu]Lu-DOTA-PP-F11N and [<sup>177</sup>Lu]Lu-DOTA-CCK-66 (IC<sub>50,inverse</sub>: 28.2–40.3 nM). [<sup>99m</sup>Tc]Tc-N<sub>4</sub>-CCK-66 and [<sup>99m</sup>Tc]Tc-N<sub>4</sub>-CCK-104 demonstrated high CCK-2R-mediated internalization (223.8 ± 0.1% and 145.2 ± 0.1% compared to [<sup>177</sup>Lu]Lu-DOTA-PP-F11N, respectively), high stability in human serum (> 95%) and similar lipophilicity (log<i>D</i><sub>7.4</sub>: − 2.09 to − 2.42) and HSA binding (47.5–53.2%) compared with [<sup>177</sup>Lu]Lu-DOTA-CCK-66. 4-(Di-<i>tert</i>-butyl(hydroxy)silyl)benzoic acid (SiOH-BA)-bearing compounds [<sup>99m</sup>Tc]Tc-N<sub>4</sub>-CCK-100 and [<sup>99m</sup>Tc]Tc-N<sub>4</sub>-CCK-103 showed an elevated lipophilicity (logD<sub>7.4</sub>: − 1.89 to − 0.95) and HSA binding (78.1–89.1%) as well as a reduced stability in human serum (87.0–93.0%), but higher internalization than [<sup>177</sup>Lu]Lu-DOTA-PP-F11N (145.0 ± 0.1% and 219.5 ± 0.1%, respectively).</p><h3>Conclusions</h3><p>Several <sup>99m</sup>Tc-labeled CCK-2R ligands with very favorable in vitro characteristics were successfully developed in this study. In particular, [<sup>99m</sup>Tc]Tc-N<sub>4</sub>-CCK-66 and [<sup>99m</sup>Tc]Tc-N<sub>4</sub>-CCK-104 are highly recommended for further evaluation in in vivo studies to examine their potential as <sup>99m</sup>Tc-based SPECT agents for improved imaging of CCK-2R-expressing malignancies. Furthermore, a possible radiotheranostic use of these N<sub>4</sub>-conjugated compounds could be explored in future studies using <sup>186/188</sup>Re.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13388586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148534951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Optimization of [18F]FBPA production for clinical translation through precursor development and manufacturing route evaluation","authors":"Ting-Yu Chang, Yu-Hou Yu, Zhen-Fan You, Ping-Chuan Cho, Yuh-Feng Wang, Chun-Yi Wu","doi":"10.1186/s41181-026-00471-x","DOIUrl":"10.1186/s41181-026-00471-x","url":null,"abstract":"<div><h3>Background</h3><p>4-Borono-2-[<sup>18</sup>F]fluorophenylalanine ([<sup>18</sup>F]FBPA) is an important imaging agent for identifying suitable candidates for boron neutron capture therapy (BNCT). This study aimed to develop three new precursors for the no-carrier-added synthesis of [<sup>18</sup>F]FBPA and to establish corresponding automated radiosynthesis protocols suitable for routine production.</p><h3>Results</h3><p>Following manual optimization, the optimized conditions were successfully translated to automated synthesis, resulting in non-decay-corrected radiochemical yields of 2.6% ± 1.3% for the BNBA-based protocol, 0.3% ± 0.1% for the P-02-based protocol, and 3.1% ± 0.0% for the P-03-based protocol, respectively. MicroPET/MR imaging and biodistribution analyses demonstrated the highest tumor uptake for [<sup>18</sup>F]FBPA-sorbitol conjugate ([<sup>18</sup>F]FBPA-Sor), followed by [<sup>18</sup>F]FBPA and [<sup>18</sup>F]FBPA-fructose conjugate ([<sup>18</sup>F]FBPA-Fr). Tumor standardized uptake values obtained from microPET/MR imaging were 1.72 ± 0.25 for [<sup>18</sup>F]FBPA, 1.29 ± 0.25 for [<sup>18</sup>F]FBPA-Fr, and 2.57 ± 0.28 for [<sup>18</sup>F]FBPA-Sor, with corresponding tumor-to-muscle (T/M) ratios of 3.34 ± 1.07, 4.64 ± 0.60, and 9.38 ± 0.88, respectively. Biodistribution studies further confirmed enhanced tumor accumulation of [<sup>18</sup>F]FBPA-Sor, with tumor uptake values of 10.46 ± 0.61, 11.51 ± 2.75, and 19.32 ± 1.57%ID/g for [<sup>18</sup>F]FBPA, [<sup>18</sup>F]FBPA-Fr, and [<sup>18</sup>F]FBPA-Sor, respectively. In addition, [<sup>18</sup>F]FBPA-Sor demonstrated the highest tumor-to-muscle and tumor-to-blood ratios, indicating that alditol conjugation significantly influences tracer pharmacokinetics and biodistribution profiles.</p><h3>Conclusions</h3><p>These findings provide practical insights into precursor design, radiosynthesis optimization, and imaging performance, offering a rational framework to guide future development and clinical translation of [<sup>18</sup>F]FBPA as a companion diagnostic for BNCT.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s41181-026-00471-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148337343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jarred Michael Scaffidi-Muta, Kwong Ching Li, Didier Boucher, Thomas Kryza, William Tieu, Andrew David Abell
{"title":"Synthesis and in vivo evaluation of a bifunctional, glutamic acid derived chelator for the 203/212Pb theranostic pair","authors":"Jarred Michael Scaffidi-Muta, Kwong Ching Li, Didier Boucher, Thomas Kryza, William Tieu, Andrew David Abell","doi":"10.1186/s41181-026-00473-9","DOIUrl":"10.1186/s41181-026-00473-9","url":null,"abstract":"<div><h3>Background</h3><p>The biodistributions of radiometalated peptides and small molecules are greatly influenced by the charge conferred by the metal-chelator complex. Careful fine-tuning of this charge thus represents an attractive method to optimise pharmacokinetic properties. For this to be an effective strategy, numerous suitable chelators must be available for a given radiometal; each possessing a different net charge. Herein we report the synthesis of 2-(4,7,10-tris(2-amino-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanedioic acid (DOTAMGA), a bifunctional chelator for the <sup>203/212</sup>Pb theranostic pair containing a single negative charge, previously unattainable with reported radiolead chelators. DOTAMGA was incorporated into a radiopharmaceutical targeting the melanocortin 1 receptor (MC1R), a receptor highly expressed by melanomas, and evaluated in vivo against the commonly used radiolead chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic amide (TCMC).</p><h3>Results</h3><p>DOTAMGA was synthesised and conjugated to the MC1R targeting peptide MC1RL for subsequent investigation alongside TCMC-MC1RL. DOTAMGA-MC1RL and TCMC-MC1RL exhibited comparable affinity for MC1R in a series of competition binding assays with MC1R expressing cells. DOTAMGA-MC1RL was effectively labelled with <sup>212</sup>Pb and <sup>203</sup>Pb under standard radiolabelling conditions, and UV–Vis experiments demonstrated more rapid Pb<sup>2+</sup> complexation than TCMC-MC1RL. Both <sup>212</sup>Pb-labelled compounds remained > 90% intact after 24 h incubation in human serum. In B16F0 melanoma bearing C57BL/6 mice, DOTAMGA-MC1RL exhibited reduced hepatic uptake compared to TCMC-MC1RL, though a reduction in tumour uptake and resulting tumour to organ uptake ratios were also observed.</p><h3>Conclusions</h3><p>DOTAMGA represents a promising tool to optimise the pharmacokinetic properties of <sup>203/212</sup>Pb radiopharmaceuticals, and is a useful addition to existing radiolead chelators on account of its unique charge.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13616893/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148387167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ashtyn McAdoo, Kamal Jouad, Eben L. Rosenthal, Adam J. Rosenberg
{"title":"Rapid assessment of target-binding fractions in molecular imaging agents using size-exclusion HPLC","authors":"Ashtyn McAdoo, Kamal Jouad, Eben L. Rosenthal, Adam J. Rosenberg","doi":"10.1186/s41181-026-00469-5","DOIUrl":"10.1186/s41181-026-00469-5","url":null,"abstract":"<div><h3>Background</h3><p>The clinical translation of molecularly targeted therapeutics and imaging agents represents a cornerstone of precision oncology, with the global theranostics market projected to exceed $25 billion by 2030. However, the development of theragnostic agents or diagnostic companions remains constrained by analytical bottlenecks in quality control, such as target-binding fraction, which are increasingly required by regulatory agencies as product release criteria during the translation process. Current methods, including enzyme-linked immunosorbent assay (ELISA), which require specialized resources or external CROs, or bead-based assays for radiolabeled compounds, which involve complex multi-step protocols; these limitations and others hamper their practical implementation in clinical manufacturing environments. Assay delays can postpone clinical trial initiation, increase development costs, and delay patient access to these agents.</p><h3>Results</h3><p>We have developed and validated a rapid, size-exclusion high-performance liquid chromatography (SE-HPLC) method for the determination of target-binding fractions of labeled biologics. The method separates the unbound biologic from the larger antigen-bound complex, allowing for rapid quantification. We validated the method using a panel of fluorescently labeled antibodies (panitumumab-IRDye800CW, nivolumab-IRDye800CW) and radiolabeled biologics ([18F]GEH200521, [18F]NOTA-ABY-030), assessing linearity, specificity, and concentration independence. The SE-HPLC method achieved excellent separation of bound and unbound species with a resolution (Rs) of 3.2. A strong linear relationship (R<sup>2</sup> = 0.999) was observed between the antigen-to-antibody ratio and the measured binding fraction. The method demonstrated high specificity, with no binding detected with non-target antigens. The total assay and analysis time was less than 35 min, a significant improvement over traditional methods.</p><h3>Conclusions</h3><p>SE-HPLC provides a rapid, specific, and cost-effective alternative to traditional binding fraction assessment methods, reducing quality control timelines from weeks/hours to minutes. The method’s compatibility with both fluorescent and radiolabeled biologics and integration with existing HPLC infrastructure represents a significant advancement in development workflows.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13617156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148387174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Elodie Duray, Matthieu Sacrez, Marine Hawotte, Charlotte Collet, Christian Vanasschen, Nicolas Veran, Corentin Warnier
{"title":"High-yield, standardised automated radiosynthesis process for routine clinical insulinoma PET with [⁶⁸Ga]Ga-NODAGA-exendin-4","authors":"Elodie Duray, Matthieu Sacrez, Marine Hawotte, Charlotte Collet, Christian Vanasschen, Nicolas Veran, Corentin Warnier","doi":"10.1186/s41181-026-00470-y","DOIUrl":"10.1186/s41181-026-00470-y","url":null,"abstract":"<div><h3>Background</h3><p>Insulinoma is a rare pancreatic neuroendocrine tumour characterised by inappropriate insulin secretion and recurrent hypoglycaemia. Owing to their small size and intrapancreatic localisation, insulinomas are frequently difficult to detect using conventional anatomical imaging techniques. Functional imaging based on positron emission tomography has therefore gained increasing interest, particularly through targeting of the glucagon-like peptide-1 receptor, which is highly overexpressed in most insulinomas. Among available tracers, gallium-68-labelled NODAGA-exendin-4 has demonstrated excellent diagnostic performance. However, its routine clinical implementation remains limited by the absence of a harmonised, robust and transferable radiosynthesis protocol compatible with hospital radiopharmacy practice. The aim of this work was to optimise and harmonise the automated preparation of gallium-68-labelled NODAGA-exendin-4 by systematically evaluating critical synthesis parameters and validating the optimised process across multiple commercially available gallium-68 generators. Using an automated synthesis module, key variables including precursor amount, labelling temperature and duration, formulation additives, workflow sequence and quality control conditions were investigated. The optimised protocol was subsequently validated using generators from three different manufacturers.</p><h3>Results</h3><p>Optimisation studies demonstrated that formulation-related parameters, particularly the post-labelling addition of polysorbate 20, resulted in improved radiochemical conversion and reduced residual activity within the synthesis cassette. An optimal precursor amount of 20 µg was identified as a compromise between radiochemical yield and clinical injectability constraints. Radiolabelling at 95 °C for 12 min ensured high conversion while reducing overall synthesis time. Validation runs showed excellent reproducibility, with non-decay-corrected yields ranging from 60 to 73% and decay-corrected yields reaching up to 93%, independent of generator type. Radiochemical purity consistently exceeded 95%, and all quality control parameters complied with established specifications.</p><h3>Conclusions</h3><p>This study establishes a simplified, efficient and generator-independent automated synthesis of gallium-68-labelled NODAGA-exendin-4. By addressing key translational and regulatory constraints, the proposed protocol provides a practical foundation for the routine clinical implementation of glucagon-like peptide-1 receptor imaging in patients with suspected insulinoma.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s41181-026-00470-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148358893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Energy dependent production and radionuclidic purity of (:{:}^{47}mathbf{S}mathbf{c}:)from (:{:}^{48}mathbf{C}mathbf{a}(varvec{p},varvec{x}varvec{n}):)reactions: a combined theoretical and data from EXFOR library using the EMPIRE code","authors":"Hailu Geremew Zeleke","doi":"10.1186/s41181-026-00463-x","DOIUrl":"10.1186/s41181-026-00463-x","url":null,"abstract":"<div><h3>Background</h3><p>The production of Scandium-47, a promising radionuclide for targeted radionuclide therapy, was investigated via proton-induced reactions on enriched Ca-48 using the EMPIRE nuclear reaction code. A comparative analysis between EMPIRE simulations and experimental data extracted from EXFOR was performed for Sc-48, Sc-47, and Sc-46 production channels, showing good overall agreement, as indicated by low MAPE values and correlation coefficients close to unity. Excitation functions for the ⁴⁸Ca(p, n)⁴⁸Sc, ⁴⁸Ca(p,2n)⁴⁷Sc, and ⁴⁸Ca(p,3n)⁴⁶Sc reactions were calculated over a wide proton energy range, and thick-target yields were evaluated using stopping power data. The RNP of ⁴⁷Sc was determined as a function of incident proton energy.</p><h3>Results</h3><p>The results show that radionuclide production strongly depends on proton energy. At low energies (0–12 MeV), the ⁴⁸Ca(p, n) reaction dominates, leading to significant ⁴⁸Sc formation and low RNP (~ 9%). In the intermediate energy range (12–28 MeV), the yield of ⁴⁷Sc increases substantially while maintaining relatively high purity. A more detailed analysis identifies the 16.5–21.5 MeV window as optimal, providing high yield with an RNP of approximately 94%. At higher energies (28–50 MeV), the increasing contribution of the ⁴⁸Ca(p,3n) reaction results in significant formation of long-lived ⁴⁶Sc, reducing radionuclidic purity.</p><h3>Conclusion</h3><p>These findings demonstrate that careful selection of the proton energy window is essential for optimizing both production yield and RNP, providing practical guidance for cyclotron-based production of ⁴⁷Sc for medical applications.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s41181-026-00463-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148337376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aivija Grundmane, Caterina F. Ramogida, Valery Radchenko
{"title":"Recycling-compatible electroplating of enriched tin-119 targets for the production of antimony-119 for targeted Auger electron therapy","authors":"Aivija Grundmane, Caterina F. Ramogida, Valery Radchenko","doi":"10.1186/s41181-026-00468-6","DOIUrl":"10.1186/s41181-026-00468-6","url":null,"abstract":"<div><h3>Background</h3><p>Antimony-119 (<sup>119</sup>Sb) is a radionuclide of interest for targeted Auger electron therapy. Isotopically pure <sup>119</sup>Sb can be produced by proton irradiation of enriched tin-119 (<sup>119</sup>Sn) targets in conventional widely available low energy medical cyclotrons. Enriched <sup>119</sup>Sn is very costly (~ 20,000 CAD/gram), requiring recycling of the target material to make this production route economically viable. Herein, we investigate three Sn electroplating methods, evaluate the target quality, as well as method compatibility with subsequent <sup>119</sup>Sb radiochemical purification steps.</p><h3>Results</h3><p>Three electroplating bath compositions (Sn(II) sulfate, Sn(IV) sols, and Sn(IV) chloride) for Sn deposition were tested and successfully implemented. One of the methods, utilizing a Sn(IV) chloride bath solution was able to achieve quantitative electroplating efficiency (98 ± 3% Sn deposited after 72 h), and an overall post-purification recovery of 84 ± 6% Sn, accounting for losses during the dissolution and purification steps. Moreover, this electroplating bath composition yielded the most homogeneous targets, both with respect to its structure, as well as lack of contaminants and the highest weight percentage of surface Sn (88 ± 2 wt%).</p><h3>Conclusions</h3><p>All three electroplating baths investigated were able to yield Sn targets of sufficient quality for irradiation, although they showed markedly different surface morphology and surface elemental composition. Sn(IV) chloride bath solution was found to be capable of recycling of <sup>119</sup>Sn as recovered from the <sup>119</sup>Sb purification step. Furthermore, this method yielded the best results in all aspects, displaying the highest homogeneity in surface morphology and elemental composition, which are desirable characteristics for beam tolerance and radionuclidic purity.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s41181-026-00468-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148337363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Joseph A. Ioppolo, Leila R. Hill, Alexander W. E. Sadler, Amit Hetsron, Laurence Morandeau, John Doan, Kenneth K. C. Hong, Andrew T. King, Tzong-Tyng Hung, Carl Power, Louis M. Rendina
{"title":"Easy and versatile preparation of 68Ga- and Al18F-labelled arylphosphonium salts from a common precursor: stability and preliminary in vivo PET/CT evaluation","authors":"Joseph A. Ioppolo, Leila R. Hill, Alexander W. E. Sadler, Amit Hetsron, Laurence Morandeau, John Doan, Kenneth K. C. Hong, Andrew T. King, Tzong-Tyng Hung, Carl Power, Louis M. Rendina","doi":"10.1186/s41181-026-00466-8","DOIUrl":"10.1186/s41181-026-00466-8","url":null,"abstract":"<div><h3>Background</h3><p>The primary aim of this work was to develop and optimise a facile synthesis of radiolabelled arylphosphonium compounds [<sup>68</sup>Ga]<b>2</b> and [<sup>18</sup>F]<b>3</b> from the common macrocyclic precursor 1-(4-(((triphenylphosphonium)yl)methyl)benzyl)-4,7-bis(carboxymethyl)-1,4,7-triazacyclononane acetate (<b>1</b>). A series of reaction conditions, including temperature, time, ethanol content and reagent concentration were tested to arrive at optimised conditions for labelling with either <sup>68</sup>Ga or Al<sup>18</sup>F. Preclinical evaluations including stability in formulation and in serum, and preliminary imaging in healthy wild type C57BL/6 mice were completed.</p><h3>Results</h3><p>The target compounds [<sup>68</sup>Ga]<b>2</b> and [<sup>18</sup>F]<b>3</b> could be prepared in near quantitative yields using the optimised conditions. Although the stability of both tracers was acceptable in formulation containing 10% ethanol and 0.5 mg/mL sodium ascorbate, and the stability of [<sup>18</sup>F]<b>3</b> in serum was ideal, the stability of [<sup>68</sup>Ga]<b>2</b> in serum was sub-optimal. Dynamic PET/CT imaging in mice over 60 min revealed no uptake in bone, rapid renal excretion and more prolonged uptake in the liver and intestine for [<sup>18</sup>F]<b>3</b> compared to [<sup>68</sup>Ga]<b>2</b>.</p><h3>Conclusion</h3><p>The simple synthesis of [<sup>68</sup>Ga]<b>2</b> and [<sup>18</sup>F]<b>3</b> from a common precursor was achieved and was easily translatable. Although the utility of [<sup>68</sup>Ga]<b>2</b> and [<sup>18</sup>F]<b>3</b> for myocardium or cancer imaging is limited, this successful labelling strategy may be applied to a library of other compounds for use in imaging other targets in the body.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s41181-026-00466-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148337327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
David Kryza, Pierre Le Fur, Jean Noël Badel, Clément Morgat, Fouzi Khayi, Anne-Laure Giraudet
{"title":"Fully GMP-complient radiosynthesis of [161Tb]Tb-PSMA-1 using the miniAiO synthesizer for clinical translation","authors":"David Kryza, Pierre Le Fur, Jean Noël Badel, Clément Morgat, Fouzi Khayi, Anne-Laure Giraudet","doi":"10.1186/s41181-026-00467-7","DOIUrl":"10.1186/s41181-026-00467-7","url":null,"abstract":"<div><h3>Background</h3><p>Terbium‑161 (<sup>161</sup>Tb) is an emerging radionuclide for targeted radionuclide therapy that combines β⁻ emissions with short‑range conversion and Auger electrons, increasing its efficacy against micrometastatic and low‑volume prostate cancer. This study aimed to develop, optimize, and validate a fully automated good manufacturing practice (GMP)-compliant radiosynthesis of [<sup>161</sup>Tb]Tb-PSMA‑1 for clinical application. Radiolabeling parameters were systematically investigated via different buffer systems (acetate, ammonium acetate, and ascorbate), labeling temperatures (24–95 °C), and ethanol supplementation. Process validation was performed on three independent batches produced under routine conditions (7.4–11.5 GBq) via a Trasis MiniAiO synthesizer. Comprehensive quality control included radionuclidic identification, radiochemical purity (RCP), pH, sterility, endotoxin testing, and container–content interaction assessment.</p><h3>Results</h3><p>Efficient radiolabeling was achieved under all the tested conditions, with RCPs consistently exceeding 97%. Optimal performance was observed when ascorbate buffer was used at 95 °C, yielding approximately 99% RCP at the end of synthesis. The addition of 40% (V/V) ethanol improved both the labeling efficiency and radiochemical stability, enabling high RCP even at lower temperatures. The final formulation demonstrated excellent stability, maintaining RCP ≥ 97.5% up to 48 h post-synthesis. All validation batches met predefined release criteria in accordance with Ph. Eur. Monograph radiopharmaceutical preparations. The total synthesis time was less than 30 min.</p><h3>Conclusion</h3><p>A robust, rapid, and fully automated GMP-compliant method for [<sup>161</sup>Tb]Tb-PSMA‑1 production was successfully established. The high radiochemical purity, stability, and reproducibility support its suitability for routine clinical use and decentralized distribution. This work represents a key step toward the clinical translation of [<sup>161</sup>Tb]Tb-labeled PSMA radioligands for improved management of advanced prostate cancer.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s41181-026-00467-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148300579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marion Berdal, Surasa Nagachinta, Ximena Langsberg, Vaiva Gaspariunaite, Sam Massa, Ana Rita Pombo Antunes, Dimitrios Mantzilas, Matthias D’Huyvetter, Laurent Navarro
{"title":"Automated and manual synthesis of [68Ga]Ga-DOTA-4AH29 intended for PET-imaging of FAP-expression","authors":"Marion Berdal, Surasa Nagachinta, Ximena Langsberg, Vaiva Gaspariunaite, Sam Massa, Ana Rita Pombo Antunes, Dimitrios Mantzilas, Matthias D’Huyvetter, Laurent Navarro","doi":"10.1186/s41181-026-00465-9","DOIUrl":"10.1186/s41181-026-00465-9","url":null,"abstract":"<div><h3>Background</h3><p>Fibroblast activation protein is a well-established target for tumour imaging, and single-domain antibodies (sdAb) offer favourable pharmacokinetic properties for PET applications. However, the translation of sdAb-based radiotracers into robust and clinically applicable manufacturing processes remains limited. Previously, preclinical protocol for the production of [<sup>68</sup>Ga]Ga-DOTA-4AH29 has been reported. In this study, this process was adapted for clinical use. Both a manual, kit-based approach and automated synthesis on two different platforms were developed. Process robustness was assessed through a stress study evaluating key parameters, and compatibility with two <sup>68</sup>Ga generator systems was investigated.</p><h3>Results</h3><p>Efficient radiolabelling was achieved at 50 °C for 10 min, with radiochemical conversion exceeding 90% and no need for purification. Both automated and manual processes showed consistent performance, with radiochemical purities of 99.5 ± 0.5% (<i>n</i> = 9) and 96.3 ± 1.5% (<i>n</i> = 8) as determined by iTLC and SE-HPLC respectively, with associated non-decay-corrected radiochemical yields of 78.3 ± 3.3% (<i>n</i> = 9) and 76.9 ± 2.1% (<i>n</i> = 8). The main source of activity loss was the radioactive decay of <sup>68</sup>Ga.The process remained stable across a range of activities and buffer conditions. Comparable results were obtained with both <sup>68</sup>Ga generator systems, with no observable impact on product quality. The final product was stable for at least 3 h at RT, with preserved binding capacity.</p><h3>Conclusion</h3><p>A robust and reproducible manufacturing process for [<sup>68</sup>Ga]Ga-DOTA-4AH29 was established, supporting both automated and manual clinical production. This approach will facilitate broader access to sdAb-based PET imaging across clinical centres.</p><h3>Graphical abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"11 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13526736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148275537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}